State Street Corp Purchases 28,525 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

State Street Corp increased its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 3.6% during the third quarter, Holdings Channel.com reports. The firm owned 822,085 shares of the medical instruments supplier’s stock after buying an additional 28,525 shares during the quarter. State Street Corp’s holdings in LeMaitre Vascular were worth $76,363,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. Townsquare Capital LLC raised its holdings in LeMaitre Vascular by 38.0% during the third quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier’s stock worth $4,454,000 after buying an additional 13,210 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of LeMaitre Vascular by 6.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier’s stock worth $17,789,000 after acquiring an additional 11,395 shares in the last quarter. Nicholas Investment Partners LP acquired a new stake in shares of LeMaitre Vascular in the 2nd quarter worth about $3,900,000. Creative Planning lifted its position in LeMaitre Vascular by 20.7% in the 3rd quarter. Creative Planning now owns 3,594 shares of the medical instruments supplier’s stock valued at $334,000 after acquiring an additional 617 shares in the last quarter. Finally, Copeland Capital Management LLC boosted its stake in LeMaitre Vascular by 1.0% during the 3rd quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier’s stock valued at $108,068,000 after purchasing an additional 11,318 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

LMAT opened at $90.93 on Wednesday. LeMaitre Vascular, Inc. has a fifty-two week low of $52.88 and a fifty-two week high of $109.58. The firm has a 50-day moving average of $97.70 and a 200 day moving average of $89.71. The firm has a market cap of $2.04 billion, a P/E ratio of 49.86, a PEG ratio of 2.47 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The firm had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company’s revenue was up 15.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.33 EPS. Equities research analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st were paid a $0.16 dividend. The ex-dividend date of this dividend was Thursday, November 21st. This represents a $0.64 annualized dividend and a dividend yield of 0.70%. LeMaitre Vascular’s payout ratio is presently 34.97%.

Insider Activity

In other news, Director Bridget A. Ross sold 3,750 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the sale, the director now owns 2,278 shares of the company’s stock, valued at $231,148.66. The trade was a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 10.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Barrington Research increased their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. JMP Securities raised their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 target price for the company. Oppenheimer reiterated an “outperform” rating and issued a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Finally, StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $94.57.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.